Calidi Biotherapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CLDI research report →
Companycalidibio.com
Calidi Biotherapeutics, Inc. , a clinical stage immuno-oncology company, engages in developing immunotherapies for the treatment of cancer. It engages in advancing a potent allogeneic stem cell capable of carrying an anti-tumor payload for use in multiple oncology indications, including high-grade gliomas and solid tumors.
- CEO
- Eric E. Poma
- IPO
- 2021
- Employees
- 28
- HQ
- San Diego, CA, US
Price Chart
Valuation
- Market Cap
- $1.25M
- P/E
- -0.09
- P/S
- 0.00
- P/B
- 0.35
- EV/EBITDA
- 0.21
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -438.03%
- ROIC
- -266.77%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-19,906,000 · 10.10%
- EPS
- $-5.95 · 83.33%
- Op Income
- $-20,240,000
- FCF YoY
- -8.64%
Performance & Tape
- 52W High
- $19.20
- 52W Low
- $0.16
- 50D MA
- $0.25
- 200D MA
- $1.30
- Beta
- 1.38
- Avg Volume
- 4.01M
Get TickerSpark's AI analysis on CLDI
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Dec 12, 25 | Camaisa Allan | sell | 850 |
| Sep 3, 25 | Poma Eric E | other | 10,000 |
| Sep 3, 25 | Fernandez Santidrian Antonio | other | 35,000 |
| Sep 3, 25 | Jackson Andrew C. | other | 30,000 |
| Aug 20, 25 | Lincoln Alternative Strategies LLC | other | 0 |
| Aug 21, 25 | Schoeneck James A | buy | 75,000 |
| Aug 21, 25 | Schoeneck James A | buy | 75,000 |
| Aug 21, 25 | Poma Eric E | buy | 25,000 |
| Aug 21, 25 | Poma Eric E | buy | 25,000 |
| Aug 21, 25 | Leftwich Scott | buy | 125,000 |
Our CLDI Coverage
We haven't published any research on CLDI yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate CLDI Report →